GCIhVIVO’s Mo Khan: “the industry is really waking up to the value of human challenge models”
Mo Khan, chief executive of (HVO ), talks to Vox Markets about the company’s latest contract win, a £13.1m deal to develop a human challenge model for Influenza B with an existing client, and how the approach is gathering momentum across the industry.
0:36 Details of the new £13.1m contract with an existing big pharma client to
develop a new human challenge model for influenza B.
2:25 How human challenge models are helping the industry develop highly-
targeted treatments, and enabling fast-tracked regulatory approval.
4:28 Next steps in the development of the influenza B human challenge model,
and the ability to leverage the model in future.
6:18 The challenges presented in developing influenza treatments, and how
human challenge models can help to bring flu under control.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.